ライフサイエンスコーパス: acute exacerbation

1 and contribute to lung function decline and acute exacerbation.

2 and the most common (40%) cause of death was acute exacerbation.

3 mediated inflammation and be associated with acute exacerbation.

4 tinuation due to clinical deterioration, and acute exacerbation.

5 risk for death after hospitalization for an acute exacerbation.

6 pithelial cells occurs in pulmonary fibrosis acute exacerbation.

7 cteristic that is usually not seen during an acute exacerbation.

8 significantly higher when patients exhibited acute exacerbation.

9 ignificant increase in SNOT-22 scores during acute exacerbation.

10 ical changes locally and systemically during acute exacerbation.

11 f smoking cessation will be needed to reduce acute exacerbations.

12 Surgical intervention prevents recurrent acute exacerbations.

13 whose disease is characterized by recurrent acute exacerbations.

14 about the details of managing patients with acute exacerbations.

15 cially studies focusing on the management of acute exacerbations.

16 or disease symptoms, including treatment for acute exacerbations.

17 to corticosteroids in reducing and treating acute exacerbations.

18 galectin-8 levels in patients with frequent acute exacerbations.

19 ars of this therapy, she manifested frequent acute exacerbations.

20 r interleukin-8 concentrations, than were no acute exacerbations.

21 onic course of COPD is worsened by recurrent acute exacerbations.

22 9% vs. 2.5%, P=0.30 by the log-rank test) or acute exacerbation (2.3% in each group, P>0.99).

23 < 0.001) and a significantly higher rate of acute exacerbations (60,320 of 165,271 in the overuse gr

24 onary fibrosis comprised 34% with idiopathic acute exacerbation (65%) being the most common admission

25 Withdrawal of phenytoin resulted in acute exacerbation, accompanied by a significantly incre

26 Acute exacerbations adversely affect patients with chron

27 otentially indicative markers of prospective acute exacerbation (AE) in interstitial lung disease (IL

28 ronic obstructive asthma (COA) and during an acute exacerbation (AE) in patients without airflow obst

29 R3 L412F in bacterial infection in IPF or in acute exacerbations (AE) has not been reported.

30 perience precipitous deteriorations, termed "acute exacerbations" (AE), marked by diffuse alveolitis

31 Rationale: Acute exacerbations (AEs) of chronic obstructive pulmona

32 The disease in mice exhibits acute exacerbation after intrapulmonary instillation of

33 The mean number of episodes of acute exacerbation after surgery was 1.6 +/- 2.3 events

34 ited 18 asthmatics admitted to hospital with acute exacerbation and 18 healthy nonsmoking controls ma

35 ohorts, one describing patients experiencing acute exacerbation and a further cohort of patients unde

36 pro-MMP-9 were also significantly higher in acute exacerbation and decreased in remission but remain

37 stane and CRP were significantly elevated in acute exacerbation and decreased in remission but remain

38 e time of clinical onset of RREAE induced an acute exacerbation and increased clinical scores, which

39 and tissue damage in patients with asthma in acute exacerbation and remission.

40 ondary end points were the time to the first acute exacerbation and the change from baseline in the t

41 an 8.9 years of follow-up, we observed 2,130 acute exacerbations and 3,973 deaths in symptomatic smok

42 Outcomes included acute exacerbations and all-cause mortality.

43 ower respiratory tract colonization and with acute exacerbations and disease progression in chronic o

44 l pathogens from sputum were the same during acute exacerbations and during stable disease.

45 Research into methods to decrease acute exacerbations and improve emergency and in-hospita

46 s (SABAs) could be associated with increased acute exacerbations and mortality in patients with asthm

47 symptomatic, with persistent symptoms and/or acute exacerbations and progressive lung function loss.

48 type 2 airway inflammation in the context of acute exacerbations and the novel treatments that effect

49 n of lung function, reduction in episodes of acute exacerbation, and enhanced longevity.

50 e clinical disease, (2) immune mechanisms of acute exacerbations, and (3) next-generation immunopheno

51 diagnosis, asthma phenotypes, severe asthma, acute exacerbations, and clinical management of disease

52 hniques, oral or intravenous antibiotics for acute exacerbations, and consideration of long-term inha

53 alizations and emergency room visits, severe acute exacerbations, and healthcare costs.

54 pitalisation (respiratory and all-cause) and acute exacerbations, and progression-free survival.

55 pidemiology of acute asthma, the triggers of acute exacerbations, and the mechanisms that underlie th

56 INTERPRETATION: Although acute exacerbations are common, the exacerbation status

57 While the factors leading to acute exacerbations are poorly understood, antibiotic tr

58 Acute exacerbations are the major cause of asthma morbid

59 re likely to have respiratory infections and acute exacerbations at baseline or to develop them subse

60 AE management involves not only treatment of acute exacerbations but also individualized patient pref

61 o control daily symptoms and prevent serious acute exacerbations, but chronic SCS use is associated w

62 ationale: Bronchiectasis is characterized by acute exacerbations, but the biological mechanisms under

63 tive measures, but admission to hospital for acute exacerbations can be expected to remain common.

64 disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or b

65 icantly increased in human IPF patients with acute exacerbation compared to patients without disease

66 of COPD at week 56, defined as the number of acute exacerbations divided by total duration of person-

67 In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95

68 Acute exacerbation during pregnancy is the most importan

69 538 (49%) of 1105 patients had at least one acute exacerbation during the 3 years of follow-up, wher

70 cy room visits, hospitalizations, and severe acute exacerbations during 2 years of PAP therapy in pat

71 82 (7%) of 1105 patients had at least one acute exacerbation each year, whereas only 23 (2%) had t

72 py significantly decreased the occurrence of acute exacerbation events, which is consistent with esta

73 C therapy had no effect on the occurrence of acute exacerbation events.

74 one (group 1), severe pain with intermittent acute exacerbations (group 2), and intermittent acute ex

75 In logistic regression, consistent acute exacerbations (>/=1 event per year for 3 years) we

76 ve pulmonary disease admitted to the ICU for acute exacerbations had abnormal breathing-swallowing in

77 and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15;

78 Analysis of acute exacerbations, hospital admissions, and time to de

79 (1)/FVC <0.70 and FEV(1) <80% predicted) and acute exacerbation hospitalizations during follow-up.

80 9) in all smokers, whereas hazard ratios for acute exacerbation hospitalizations were 4.16 (95% CI, 1

81 e 2 inflammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted ant

82 atic subjects of similar ages can experience acute exacerbation in an environmental chamber that rese

83 es lung fibrosis by significantly inhibiting acute exacerbation in the human transforming growth fact

84 d in patients with COPD who experienced more acute exacerbation in the previous year.

85 atinine; range, 70 to 110) (p < 0.001) as an acute exacerbation in their clinical condition resolved.

86 learance and pulmonary function, and reduces acute exacerbations in CF patients.

87 more than 1000 genes was upregulated during acute exacerbations in comparison with 7 to 14 days late

88 h year, whereas only 23 (2%) had two or more acute exacerbations in each year.

89 ommonly causing otitis media in children and acute exacerbations in patients suffering from chronic o

90 ciated with increased rates of mortality and acute exacerbations in patients with asthma, supporting

91 g cause of lung infections and contribute to acute exacerbations in patients with chronic respiratory

92 wice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonar

93 offer a novel adjunctive treatment to limit acute exacerbations in patients with IPF.

94 i-HSP70 isolated from patients with IPF with acute exacerbations increased Bcl-2 expression in human

95 ability (outpatients) and 13 patients during acute exacerbation (inpatients).

96 , the use of macrolides in chronic asthma or acute exacerbations is not justified.

97 iversity of airway microbiota, whose role in acute exacerbations is unclear.

98 nosinusitis (CRS) is complicated by frequent acute exacerbations leading to significant health care b

99 -free survival was defined as time to death, acute exacerbation, lung transplant, or decrease in forc

100 Patients with acute exacerbations may benefit from the addition of inh

101 Although acute exacerbations, mostly triggered by viruses, accoun

102 An estimated 7,511,267 admissions for acute exacerbations occurred from 1998 to 2008.

103 After surgery, no acute exacerbations occurred in 42 of 64 (66%) group 2 p

104 producing: [1] hyperacusis, together with an acute exacerbation of [2] chronic aberrant Type-I neural

105 characterized by bacterial colonization and acute exacerbation of airway infections, we assessed whe

106 Differences in sputum microbial profiles at acute exacerbation of airways disease are reflected by t

107 te overlapping risk factors and symptoms, an acute exacerbation of asthma or an episode of acute ches

108 sthma were enrolled within 24 hours after an acute exacerbation of asthma requiring short-term medica

109 ncarceration presented to a free clinic with acute exacerbation of back pain triggered by carrying he

110 e in-hospital management of patients with an acute exacerbation of chronic heart failure.

111 , and in group 3 (n = 10) were patients with acute exacerbation of chronic liver disease.

112 Community-acquired pneumonia (CAP) and acute exacerbation of chronic obstructive pulmonary dise

113 re beneficial for patients hospitalized with acute exacerbation of chronic obstructive pulmonary dise

114 n, ischemic stroke, urinary tract infection, acute exacerbation of chronic obstructive pulmonary dise

115 s with cardiogenic pulmonary edema (n = 97), acute exacerbation of chronic obstructive pulmonary dise

116 ciated with community acquired pneumonia and acute exacerbation of chronic obstructive pulmonary dise

117 Acute exacerbation of chronic obstructive pulmonary dise

118 re often used in the outpatient treatment of acute exacerbation of chronic obstructive pulmonary dise

119 infection (uUTI), acute sinusitis (AS), and acute exacerbation of chronic obstructive pulmonary dise

120 ay affect non-COVID-19 admissions for severe acute exacerbation of chronic obstructive pulmonary dise

121 ]), upper respiratory tract infection and/or acute exacerbation of chronic obstructive pulmonary dise

122 ents with acute HF, but not in patients with acute exacerbation of chronic obstructive pulmonary dise

123 We studied 1,298 patients hospitalized with acute exacerbation of congestive heart failure who were

124 ing cardiologist care among patients with an acute exacerbation of congestive heart failure.

125 -intensity adverse event in both studies was acute exacerbation of COPD (1-4 [<1-2%] patients across

126 in both systemic and airway inflammation and acute exacerbation of COPD (AECOPD) has been reported by

127 ks (RRs) and 95% CIs for hospitalisation for acute exacerbation of COPD associated with pollutant con

128 S hospitals involving patients admitted with acute exacerbation of COPD in 2006 and 2007 to a non-int

129 Among patients hospitalized for acute exacerbation of COPD low-dose steroids administere

130 (P=0.01), and the hazard ratio for having an acute exacerbation of COPD per patient-year in the azith

131 eatment failure at day 30 (ie, recurrence of acute exacerbation of COPD resulting in emergency room v

132 ration, RRs for same-day hospitalisation for acute exacerbation of COPD were 1.029 (95% CI 1.023-1.03

133 nts presenting with signs and symptoms of an acute exacerbation of COPD were prospectively randomized

134 o Dec 31, 2017, 161 613 hospitalisations for acute exacerbation of COPD were recorded.

135 nts with persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive vent

136 , with moderate-to-severe COPD, at least one acute exacerbation of COPD, and a sputum eosinophil coun

137 acceptable, and transportable definition of acute exacerbation of COPD, as well as improved methods

138 admitted to hospital for more than 24 h for acute exacerbation of COPD.

139 edical practices in England and Wales for an acute exacerbation of COPD.

140 result from either acute limb ischemia or an acute exacerbation of critical limb ischemia.

141 fy clinical factors associated with frequent acute exacerbation of CRS (AECRS).

142 Immunological changes during acute exacerbation of CRS may provide valuable clues to

143 motherapy and can effectively prevent severe acute exacerbation of HBV infection in hospitals among H

144 ng PMX-DHP and SHEDD-fA may be used to treat acute exacerbation of idiopathic interstitial pneumonias

145 outcomes of patients with steroid-resistant acute exacerbation of idiopathic interstitial pneumonias

146 Acute exacerbation of idiopathic pulmonary fibrosis is a

147 ality was 2% (one of 65 patients), following acute exacerbation of idiopathic pulmonary fibrosis.

148 Acute exacerbation of IIPs is now well defined.

149 failure in clinical AA amyloidosis following acute exacerbation of inflammation.

150 Acute exacerbation of IPF was suspected.

151 of acute worsening of their disease, termed acute exacerbation of IPF, which may be caused by bacter

152 at bacteria shedding corisin are involved in acute exacerbation of IPF, yielding insights to the mole

153 at the beginning and end of treatment for an acute exacerbation of lung infection and again 3 wk late

154 elapse or insufficient clinical response and acute exacerbation of OCD symptoms.

155 due to relapse or insufficient response, or acute exacerbation of OCD symptoms.

156 report a case of simultaneous occurrence of acute exacerbation of ocular graft-versus-host disease (

157 ware of rare refractory anterior uveitis and acute exacerbation of ocular GVHD after COVID-19 vaccina

158 stem cell transplantation (HSCT), developed acute exacerbation of ocular GVHD and anterior uveitis a

159 stress occurs in the sickle kidney, and that acute exacerbation of oxidative stress in the sickle mou

160 tus and antipsychotic treatment following an acute exacerbation of psychosis.

161 status and antipsychotic treatment after an acute exacerbation of psychosis.

162 mitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly

163 e the role of corisin in the pathogenesis of acute exacerbation of pulmonary fibrosis and acute lung

164 orisin, a proapoptotic peptide that triggers acute exacerbation of pulmonary fibrosis.

165 olerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective d

166 of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable saf

167 this 4-week trial involving patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D

168 versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia.

169 y and safety of SEP-363856 in adults with an acute exacerbation of schizophrenia.

170 he outcomes of patients hospitalized with an acute exacerbation of severe chronic obstructive pulmona

171 l response (9% versus 24%, respectively) and acute exacerbation of symptoms (12% versus 35%).

172 ed risk of post-exertional malaise (PEM), an acute exacerbation of symptoms and other related outcome

173 ve a high symptom burden, and many report an acute exacerbation of symptoms immediately after in-cent

174 ypothesis) that ACLF is the expression of an acute exacerbation of the SI already present in decompen

175 in the United States each year experience an acute exacerbation of their asthma, a quarter of which r

176 up-regulated by rhinovirus infection during acute exacerbations of asthma and chronic obstructive pu

177 Air pollution contributes to acute exacerbations of asthma and the development of ast

178 identify pregnancy-related risk factors for acute exacerbations of asthma during pregnancy.

179 n is now recognized as an important cause of acute exacerbations of asthma in school-aged children.

180 for chronic treatment and intravenously for acute exacerbations of asthma).

181 al infections contribute to the causation of acute exacerbations of asthma, but that additional cofac

182 Viruses are frequently associated with acute exacerbations of asthma, but the extent to which t

183 rove the pulmonary function of patients with acute exacerbations of asthma, but their effect on hospi

184 athway is involved in both the onset and the acute exacerbations of asthma.

185 e efficacy of telithromycin in patients with acute exacerbations of asthma.

186 e linked to neutrophilic inflammation during acute exacerbations of asthma.

187 he benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit

188 etiologies of diseases such as pneumonia and acute exacerbations of chronic bronchitis.

189 infections are associated with morbidity and acute exacerbations of chronic lung diseases, such as cy

190 an important cause of acute lung injury and acute exacerbations of chronic obstructive pulmonary dis

191 From 1998 to 2010, patients with acute exacerbations of chronic obstructive pulmonary dis

192 course of systemic glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary dis

193 een 1998 and 2010, severity and mortality of acute exacerbations of chronic obstructive pulmonary dis

194 Fourteen thousand four hundred forty acute exacerbations of chronic obstructive pulmonary dis

195 ion (NIPPV) use in patients hospitalized for acute exacerbations of chronic obstructive pulmonary dis

196 Guidelines recommend antibiotic therapy for acute exacerbations of chronic obstructive pulmonary dis

197 It has been associated with acute exacerbations of chronic obstructive pulmonary dis

198 oids are routinely used for the treatment of acute exacerbations of chronic obstructive pulmonary dis

199 The role of bacterial pathogens in acute exacerbations of chronic obstructive pulmonary dis

200 g a new test lung model designed to simulate acute exacerbations of chronic obstructive pulmonary dis

201 tially playing a role in the pathogenesis of acute exacerbations of chronic obstructive pulmonary dis

202 ntibiotics without harming patients who have acute exacerbations of chronic obstructive pulmonary dis

203 was to describe changes in the management of acute exacerbations of chronic obstructive pulmonary dis

204 Rationale: Acute exacerbations of chronic obstructive pulmonary dis

205 Severe acute exacerbations of chronic obstructive pulmonary dis

206 l in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Dis

207 Patients admitted with acute exacerbations of chronic obstructive pulmonary dis

208 alth by investigating the number of cases of acute exacerbations of chronic obstructive pulmonary dis

209 is the primary cause of bacterially induced acute exacerbations of chronic obstructive pulmonary dis

210 th systemic corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary dis

211 Rationale: Azithromycin prevents acute exacerbations of chronic obstructive pulmonary dis

212 RATIONALE: Acute exacerbations of chronic obstructive pulmonary dis

213 Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary dis

214 , long appreciated as one of the triggers of acute exacerbations of chronic pulmonary diseases, has r

215 iolitis in infancy, childhood pneumonia, and acute exacerbations of chronic respiratory diseases such

216 Acute exacerbations of chronic rhinosinusitis (AECRS) ar

217 61%), and had lower rates of readmission for acute exacerbations of COPD (7.91%; 95% CI, 7.89%-7.94%

218 ould be associated with an increased risk of acute exacerbations of COPD (AECOPD).

219 To determine the association between acute exacerbations of COPD (and acute respiratory event

220 to recommended inpatient care treatments for acute exacerbations of COPD (recommended care, nonrecomm

221 uary 1, 2006, through December 31, 2007, for acute exacerbations of COPD at 413 acute care facilities

222 primary endpoint was the annualised rate of acute exacerbations of COPD at week 56, defined as the n

223 In 2013, there were 12 679 acute exacerbations of COPD cases that were advanced by

224 izumab did not reduce the annualised rate of acute exacerbations of COPD compared with placebo in the

225 compare factors associated with one or more acute exacerbations of COPD every year for 3 years versu

226 ss the pattern and outcomes of NIPPV use for acute exacerbations of COPD from 1998 to 2008.

227 sociated with increased hospitalisations for acute exacerbations of COPD in Beijing.

228 ed to establish whether benralizumab reduces acute exacerbations of COPD in patients with eosinophili

229 d intervention to support self-management of acute exacerbations of COPD in three resource-poor setti

230 uality of care for patients hospitalized for acute exacerbations of COPD may be improved by increasin

231 ved outcomes among patients hospitalized for acute exacerbations of COPD regardless of the risk of tr

232 r the hypercarbia developed by patients with acute exacerbations of COPD when treated with supplement

233 were patient-reported use of antibiotics for acute exacerbations of COPD within 4 weeks after randomi

234 presenting to the emergency department with acute exacerbations of COPD, 5-day treatment with system

235 ical, albeit non-significant, improvement in acute exacerbations of COPD, SGRQ-C, CRQ-SAS, and FEV1 w

236 ly over time among patients hospitalized for acute exacerbations of COPD, whereas the need for intuba

237 ebo, benralizumab did not reduce the rate of acute exacerbations of COPD.

238 e use of a 5-day glucocorticoid treatment in acute exacerbations of COPD.

239 intubation and the mortality associated with acute exacerbations of COPD.

240 ntion due to oxygen therapy in patients with acute exacerbations of COPD.

241 posure in patients admitted to hospital with acute exacerbations of COPD.

242 ro studies, fibrosis reduces the severity of acute exacerbations of CP by reducing lipolytic flux bet

243 le to respiratory infections contributing to acute exacerbations of disease.

244 Inpatients with acute exacerbations of DSM-III schizophrenia (N = 66) we

245 This severe phenotype resembled acute exacerbations of generalised pustular psoriasis (G

246 B coinfection were more likely to experience acute exacerbations of hepatitis, HBeAg seroconversion,

247 Acute exacerbations of idiopathic pulmonary fibrosis (AE

248 ibrosis (IPF) and increases the incidence of acute exacerbations of IPF.

249 d the number and hospitalization duration of acute exacerbations of IPF.

250 novel therapeutic target to protect against acute exacerbations of IPF.

251 of 434 children (2 to 18 years old) who had acute exacerbations of moderate or severe asthma treated

252 hing 50% internationally in the incidence of acute exacerbations of preexisting chronic respiratory d

253 dinal studies of antipsychotic treatment for acute exacerbations of psychosis (p < .01 for each).

254 arameters (CD4/CD8) may be state markers for acute exacerbations of psychosis, others (CD56) may be t

255 d plasma nitrite) might be state markers for acute exacerbations of psychosis, others (RBC superoxide

256 reased following antipsychotic treatment for acute exacerbations of psychosis.

257 es with a proinflammatory phenotype mediates acute exacerbations of pulmonary fibrosis, and targeting

258 For acute exacerbations of schizoaffective disorder or of sc

259 l placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investiga

260 ns and administration routes) in adults with acute exacerbations of schizophrenia.

261 odel and supports its potential use to treat acute exacerbations of the disease.

262 reliable way to identify hTTP, as outside of acute exacerbations of TTP, donors with hTTP can have no

263 Acute exacerbations of underlying COPD are a common caus

264 ajor interferon producers is impaired during acute exacerbations of wheeze.

265 subset of patients with CP have intermittent acute exacerbations, often with increasing frequency and

266 te exacerbations (group 2), and intermittent acute exacerbations only (group 3).

267 ession of such diseases, often punctuated by acute exacerbations or secondary illnesses, can lead to

268 Among patients who had any acute exacerbation over 3 years, very few repeatedly had

269 who died (P = 0.008), and 70% of those with acute exacerbations (P = 0.0005).

270 pulmonary artery hypertension (P = 0.01) or acute exacerbations (P = 0.002).

271 During acute exacerbation, peripheral blood SAA levels increase

272 No differences in the frequency of acute exacerbations, pneumonia, or hospitalization were

273 COPD (r(s) = 0.156, P < 0.01), frequency of acute exacerbation (r(s) = 0.114, P < 0.05), mMRC score

274 Additionally, the severe HBV acute exacerbation rate in the therapeutic control stage

275 rate, HBV prophylactic rate, and severe HBV acute exacerbation rate were compared between stages wit

276 s (HR = 0.78, 95% CI = 0.69-0.89), and lower acute exacerbation rates (HR = 0.59, 95% CI = 0.53-0.65)

277 nol abuse, pain, narcotic use, and recurrent acute exacerbations requiring hospital admission before

278 safe and well tolerated in CF patients with acute exacerbations requiring hospitalization, but the s

279 ncy department visits, and a reduced risk of acute exacerbations, respiratory symptoms, and respirato

280 s and controls, which rose sharply during an acute exacerbation suggesting that galectin-3 may be a m

281 atment for patients with severe COPD with an acute exacerbation that includes increased sputum purule

282 introducing Tio, none of the patients had an acute exacerbation that required hospitalization and the

283 COPD is frequently punctuated by acute exacerbations that are precipitated primarily by i

284 t complication of advanced COPD and predicts acute exacerbations, though pulmonary vascular abnormali

285 hotomous measures of all-cause mortality and acute exacerbations using random-effects models and Mant

286 in 54 patients with COPD examined during an acute exacerbation (V1) and 2 months afterward (V2) and

287 hromycin group the hazard risk for having an acute exacerbation was 0.5 (95% CI, 0.3-0.9; P = .03), a

288 hat in men, the incidence of death caused by acute exacerbation was higher and that caused by cardiov

289 d participants to determine if treatment for acute exacerbation was required.

290 The mean rate of acute exacerbations was 6.3 +/- 2.1 events per year befo

291 om asthmatic patients with stable disease or acute exacerbations was further studied to determine the

292 An increased risk of acute exacerbations was observed in retrospective cohort

293 sistent pattern (both years with and without acute exacerbations) was common (456 [41%] of the group)

294 obiome before, at the onset of, and after an acute exacerbation were examined in 60 sputum samples co

295 Patients with schizophrenia experiencing an acute exacerbation were randomly assigned to daily brexp

296 Acute exacerbations were primarily respiratory (five pat

297 ional morbidity and mortality are related to acute exacerbations, which are associated with further m

298 nchiectasis were enrolled and presented with acute exacerbations within 12 months.